FastPharming™ Tech

Glycan Engineering

With increasing commercial opportunities for biotherapeutics across global markets, demands are as high as ever for technologies that can support production of complex glycoproteins. N-linked glycosylation is a critical post-translational modification to an original, naked protein that influences biological activity, protein conformation, stability, solubility, secretion, pharmacokinetics (PK), and antigenicity.1

Consequently, the ability to control N-glycosylation is necessary for 21st century antibody engineering. Now, with iBio’s new FastGlycaneeringTM Development Service, iBio can provide the power, speed and control needed to develop next-gen monoclonal antibodies, biobetters, and fast-follower products. 

DEVELOPMENT SERVICES

Why FastGlycaneering?


Consistency

iBio's N. benthamiana expression system delivers products with inherently greater homogeneity versus traditional platforms:

  • Bacteria do not glycosylate. Yeast hyperglycosylate, and Chinese hamster ovary (CHO) cell lines do not precisely mimic human glycosylation patterns.
  • Plants do not naturally attach α1,6-fucose, terminal β1,4-galactose residues or any sialic acid residues, leading to simpler, more homogeneous N-linked glycosylation patterns.

Afucosylation

Desirable afucosylated G0, G1 and G2 side chains can be engineered via the removal of plant-specific sugars (core α1,3-fucose and β1,2-xylose) and the addition of terminal β1,4-galactose residues to enhance effector functions, especially antibody-dependent cell-mediated cytotoxicity [ADCC].2,3

Oligomannose Modification

FastGlycaneering enables the production of glycoproteins exclusively decorated with oligomannose residues – without altering the amino acid sequence of the target protein. This can be useful for the development of lysosomal enzymes, proteins with a high clearance rate, or certain effector functions.

iBio Offers Customized N-Glycosylation To Meet Your Target Product Profile


01_standard_plant

Standard Plant N-Glycans

In wild-type plants

  • More homogenous
  • No sialylation
  • No galactose capping
02_Afucosylated_NGlycans

Afucosated N-Glycans

In knock-out plant line

  • Increased ADCC*
  • No sialylation
  • No galactose capping
03_Afucosylated_Humanized

Afucosylated Humanized
N-Glycans

Use of knock-out / knock-in
plant line

  • Increased ADCC*
  • Galactose capping (G2)
  • No sialylation
04_Humanized_NGlycans

Humanized N-Glycans

Use of knock-out / knock-in
plant line

  • Human glycoform with α1,6-fucose
  • Biosimilar option
  • No sialylation
05_Oligomannose_NGlycans

Oligomannose N-Glycans

Use of a Mannosidase inhibitor
treatment

  • Increased cellular drug uptake
  • Lower serum half-life
  • Increased ADCC*